Autres langues Eisai Co., Ltd.

Actions

4523

JP3160400002

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
6 240 ^JPY	-0,30%		+5,74%	-11,51%

24/04	Biogen dépasse les estimations de bénéfices trimestriels, les ventes de médicaments contre la maladie d'Alzheimer augmentent	RE
23/04	L'adoption d'un médicament contre la maladie d'Alzheimer aux États-Unis est ralentie par le scepticisme des médecins	RE

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioArctic AB - Leqembi revenue totaled JPY 2.83 billion in the first quarter 2024	25/04
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024	24/04
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	24/04
Alzheimer's drug adoption in US slowed by doctors' skepticism	23/04
BioArctic and Eisai sign research evaluation agreement regarding BAN2802	20/04
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)	18/04
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan	17/04
It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?	13/04
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics	03/04
Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	01/04
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	01/04
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	01/04
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed	01/04
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	01/04
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical	29/03
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture	29/03
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024	29/03
BioArctic AB - Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	25/03
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	22/03
Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	22/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Eisai Co., Ltd.

Actions

4523

JP3160400002

Autres langues

Filtres